Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors

Advances in Therapy

Volumn 26, Issue 1, 2009, Pages 68-88

  Knight, Chris ^a   Danø, Anne Møller ^b   Kennedy Martin, Tessa ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b NOVO NORDISK A S   (Denmark)

^c KMHO   (United Kingdom)

Author keywords

APCC; Efficacy; Hemophilia; RFVIIa; Systematic review

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AMNESIA; BLEEDING; BLEEDING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EMBASE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MEDLINE; META ANALYSIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE;

BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; HEMOPHILIA A; HUMANS; META-ANALYSIS AS TOPIC; PAIN; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 73449104724     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0135-6     Document Type: Review

References (28)

1. J. Astermark S.M. Donfield D.M. DiMichele 2007 A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study Blood 109 546 551 16990605 10.1182/blood-2006-04- 017988 1:CAS:528:DC%2BD2sXivVyku7g%3D (Pubitemid 46105952)
2. G. Young F.E. Shafer P. Rojas S. Seremetis 2008 Single 270μg kg -1 dose rFVIIa vs. standard 90 μg kg -1 dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison Haemophilia 14 287 294 18081834 10.1111/j.1365-2516.2007.01601.x 1:CAS:528:DC%2BD1cXksFSntrk%3D (Pubitemid 351338689)
3. J.M. Lusher H.R. Roberts G. Davignon 1998 A randomized double-blind comparison of low dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors Haemophilia 4 790 798 10028299 10.1046/j.1365-2516.1998.00209.x 1:STN:280:DyaK1M7lt1KmsQ%3D%3D (Pubitemid 28561369)
4. E. Santagostino M.E. Mancuso A. Rocino G. Mancuso F. Scaraggi P.M. Mannucci 2006 A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors J Thromb Haemost. 4 367 371 16420567 10.1111/j.1538-7836.2006.01772.x 1:CAS:528:DC%2BD28XisVSju7g%3D
5. K. Kavakli M. Makris B. Zulfikar 2006 Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors Thromb Haemost. 95 600 605 16601828 1:CAS:528:DC%2BD28XksFWqsro%3D
6. L.J.M. Sjamsoedin L. Heijnen E.P. Mauser-Bunschoten 1981 The effect of activated prothrombincomplex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII N Engl J Med. 305 717 721 6790990 1:STN:280:Bi6B2s%2FmtFE%3D
7. M.W. Hilgartner G.L. Knatterud 1983 FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors Blood 61 36 40 6401216 1:STN:280:BiyD2srovVw%3D
8. M. Hilgartner L. Aledort A. Andes J. Gill 1990 FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients Transfusion 30 626 630 2402777 10.1046/j.1537-2995.1990. 30790385521.x 1:STN:280:By%2BA1crlt1U%3D
9. D. DiMichele C. Negrier 2006 A retrospective postlicensure survey of FEIBA efficacy and safety Haemophilia 12 352 362 16834734 10.1111/j.1365-2516. 2006.01284.x 1:STN:280:DC%2BD28vht1Oruw%3D%3D
10. C. Negrier J. Goudemand Y. Sultan 1997 Multicenter retrospective study on the utlization of FEIBA in France in patients with factor VIII and factor IX inhibitors Thromb Haemost. 77 1113 1119 9241742 1:CAS:528:DyaK2sXksFKlurk%3D
11. C. Negrier 1998 French FEIBA Study Group. FEIBA VH in home treatment - a 3-year experience Haemophilia. 4 238
12. N.S. Key L.M. Aledort D. Beardsley 1998 Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors Thromb Haemost. 80 912 918 9869160 1:CAS:528:DyaK1cXotVSlsrk%3D
13. A. Shirahata T. Kamiya J. Takamatsu 2001 Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors Int J Hematol. 73 517 525 11503968 10.1007/BF02994016 1:CAS:528:DC%2BD3MXlslaku7Y%3D
14. R. Parameswaran A.D. Shapiro J.C. Gill C.M. Kessler 2005 HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry Haemophilia. 11 100 106 15810910 10.1111/j.1365-2516.2005.01075.x 1:CAS:528:DC%2BD2MXjsFKmtLY%3D (Pubitemid 40468056)
15. R.M. Bech 1996 Recombinant factor VIIa in joint and muscle bleeding episodes Haemostasis. 26 suppl.1 135 138 8904188 1:CAS:528:DyaK28XitlKku7c%3D
16. Y. Laurian J. Goudemand C. Negrier 1998 Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study) Blood Coagul Fibrinolysis 9 suppl.1 S155 S156
17. E. Santagostino A. Gringeri P.M. Mannucci 1999 Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention Br J Haematol. 104 22 26 10027707 10.1046/j.1365-2141.1999.01128.x 1:CAS:528:DyaK1MXhsF2lt78%3D (Pubitemid 29037013)
18. C.R. Hay S. Brown P.W. Collins D.M. Keeling R. Liesner 2006 The diagnoses and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation Br J Haematol. 133 591 605 16704433 10.1111/j.1365-2141.2006.06087.x 1:CAS:528:DC%2BD28XmslCrs78%3D (Pubitemid 43742773)
19. M.J. Treur F. McCracken B. Heeg 2007 Efficacy of recombinant activated factor VII (rFVIIa) vs. activated prothrombin complex concentrate (APCC) in patients with hemophilia with inhibitors: a Bayesian meta-analysis Blood 110 3964
20. J.M. Lusher 2000 Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII Blood Coagul Fibrinolysis 11 suppl.1 S45 S49 10850564 1:CAS:528:DC%2BD3cXktlGisbc%3D
21. Prescribing information for NovoSeven ®. Revised May 2008. Available at: www.fda.gov/CBER/label/novosevenrtLB.pdf. Accessed November 2008.
22. E.P. Mauser-Bunschoten H.K. Nieuwenhuis G. Roosendaal H.M. van den Berg 1995 Low-dose immune tolerance induction in hemophilia A patients with inhibitors Blood 86 983 988 7620189 1:CAS:528:DyaK2MXnt1Sru70%3D
23. H.H. Brackmann E. Effenberger L. Hess R. Schwaab J. Oldenburg 2000 NovoSeven in immune tolerance therapy Blood Coagul Fibrinolysis 11 suppl.1 S39 S44 10850563 1:CAS:528:DC%2BD3cXktlGisbY%3D
24. Chow S-C, ed. Encyclopedia of Biopharmaceutical Statistics. 2nd edition. Informa Healthcare; 2003.
25. A.H. Miners C.A. Sabin K.H. Tolley C. Jenkinson P. Kind C.A. Lee 1999 Assessing health-related quality-of-life in individuals with haemophilia Haemophilia 5 378 385 10583523 10.1046/j.1365-2516.1999.00347.x 1:STN:280:DC%2BD3c%2FltFSmtQ%3D%3D (Pubitemid 30003764)
26. H. Luu B. Ewenstein 2004 FEIBA safety profile in multiple modes of clinical and home-therapy application Haemophilia 10 suppl.2 10 16 15385041 10.1111/j.1365-2516.2004.00935.x 1:CAS:528:DC%2BD2MXktlGqtQ%3D%3D
27. E. Santagostino P.M. Mannucci A. Gringeri 1997 Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization Transfusion 37 517 522 9149778 10.1046/j.1537-2995.1997. 37597293884.x 1:CAS:528:DyaK2sXjtlOgu78%3D
28. J.M. Soucie E.B. Siwak W.C. Hooper B.L. Evatt F.B. Hollinger 2004 Universal Data Collection Project Working Group. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation Transfusion 44 1179 1185 15265122 10.1111/j.1537-2995.2004.04029.x (Pubitemid 38989750)